---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-097851"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2026-09-08T12:00:30+00:00"
generated_at: "2026-09-08T12:05:12.870837+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics CMO – Urology Raj Pruthi departs effective Sept 3, 2026

## Summary
- Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026.
- No replacement or successor for the CMO – Urology role was named in the filing.
- Departure was reported under Item 8.01; no reason or transition details provided.

## SEC filing metadata
- accession: 0001213900-26-097851
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2026-09-08T12:00:30+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/0001213900-26-097851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/ea0304768-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-097851
- JSON: https://secwatch.observer/filing/0001213900-26-097851.json
- Plain text: https://secwatch.observer/filing/0001213900-26-097851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.